SCTX · Forms 3, 4, 5
Insider trades at Scribe Therapeutics, Inc.
6 insiders bought $71.3M of Scribe Therapeutics, Inc. stock on the open market in the last 90 days.
Every Form 3, 4 and 5 filed for Scribe Therapeutics, Inc. (SCTX) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Insider trades in the last 90 days
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Behzad Aghazadeh | Director | Buy | 7,905 | $18.25 | $144K | Form 4 | |
| Brett Staahl | 10% owner | Options or other derivatives | Form 4 | ||||
| AH Bio Fund II, L.P. | 10% owner | Conversion | 2,051,742 | Form 4 | |||
| AH Bio Fund II, L.P. | 10% owner | Conversion | 697,650 | Form 4 | |||
| AH Bio Fund II, L.P. | 10% owner | Buy | 333,333 | $15.00 | $5M | Form 4 | |
| Carl L Gordon | Director | Conversion | 348,825 | Form 4 | |||
| Carl L Gordon | Director | Buy | 1,000,000 | $15.00 | $15M | Form 4 | |
| ORBIMED ADVISORS LLC | Director | Conversion | 348,825 | Form 4 | |||
| ORBIMED ADVISORS LLC | Director | Buy | 1,000,000 | $15.00 | $15M | Form 4 | |
| Jennifer A Doudna | 10% owner | Conversion | 12,511 | Form 4 | |||
| Benjamin L. Oakes | President, CEO | Options or other derivatives | Form 4 | ||||
| Carl L Gordon | Director | Options or other derivatives | Form 4 | ||||
| James Dean Watson | Director | Options or other derivatives | Form 4 | ||||
| Joshua Bleharski | Director | Options or other derivatives | Form 4 | ||||
| Behzad Aghazadeh | Director | Options or other derivatives | Form 4 | ||||
| Behzad Aghazadeh | Director | Buy | 2,333,333 | $15.00 | $35M | Form 4 | |
| Behzad Aghazadeh | Director | Buy | 50,000 | $22.31 | $1.1M | Form 4 | |
| Svetlana Lucas | Chief Business Officer | Buy | 3,000 | $15.00 | $45K | Form 4 | |
| David Parrot | Chief Financial Officer | Buy | 1,333 | $15.00 | $20K | Form 4 | |
| David Parrot | Chief Financial Officer | Buy | 1,333 | $15.00 | $20K | Form 4 | |
| ELI LILLY & Co | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| ORBIMED ADVISORS LLC | Director | Became an insider (Form 3) | Form 3 | ||||
| AH Bio Fund II, L.P. | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| Brett Staahl | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| Jennifer A Doudna | 10% owner | Became an insider (Form 3) | Form 3 | ||||
| Carl L Gordon | Director | Became an insider (Form 3) | Form 3 | ||||
| James Dean Watson | Director | Became an insider (Form 3) | Form 3 | ||||
| Svetlana Lucas | Chief Business Officer | Became an insider (Form 3) | Form 3 | ||||
| Benjamin L. Oakes | President, CEO | Became an insider (Form 3) | Form 3 | ||||
| Joshua Bleharski | Director | Became an insider (Form 3) | Form 3 | ||||
| David Parrot | Chief Financial Officer | Became an insider (Form 3) | Form 3 | ||||
| Behzad Aghazadeh | Director | Became an insider (Form 3) | Form 3 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.